PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population

被引:20
|
作者
Sushma, P. S. [1 ]
Jamil, Kaiser [2 ]
Kumar, P. Uday [1 ]
Satyanarayana, U. [3 ]
Ramakrishna, M. [4 ,5 ]
Triveni, B. [4 ,5 ]
机构
[1] Natl Inst Nutr ICMR, Dept Pathol, Hyderabad, Telangana, India
[2] Bhagwan Mahavir Med Res Ctr, Dept Genet, Hyderabad 500004, Telangana, India
[3] Dr Pinnamaneni Siddhartha Inst Med Sci, Dept Biochem, Gannavaram, AP, India
[4] MNJ Inst Oncol, Hyderabad, Telangana, India
[5] Reg Canc Ctr, Hyderabad, Telangana, India
关键词
Methylation-specific PCR (MSP); Oral squamous cell carcinoma (OSCC); Epigenetics; PTEN; p16; Biomarkers; TUMOR-SUPPRESSOR GENE; SOFT-TISSUE SARCOMAS; PROMOTER HYPERMETHYLATION; PROTEIN EXPRESSION; DNA METHYLATION; GASTRIC-CANCER; HEAD; INACTIVATION; PATHWAY; GROWTH;
D O I
10.1007/s13277-015-4648-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphatase and tensin homolog (PTEN) and p16INK4a (p16) genes are tumor suppressor genes, associated with epigenetic alterations. PTEN and p16 promoter hypermethylation is a major epigenetic silencing mechanism leading to cancer. The cooperation between PTEN and p16 in pathogenesis of cancers suggest that their combination might be considered as potential molecular marker for specific subgroups of patients. Hence, the present study aimed to investigate whether PTEN and p16 promoter methylations were involved in oral squamous cell carcinoma (OSCC) in south Indian subjects. DNA methylation quantitative analyses of the two candidate tumor suppressor genes PTEN and p16 were performed by methylation-specific polymerase chain reaction (MSP). Fifty OSCC biopsy samples and their corresponding non-malignant portions as controls were studied comparatively. The methylation status was correlated with the clinical manifestations. Twelve out of 50 patients (24 %) were found to be methylated for PTEN gene, whereas methylation of the p16 gene occurred in 19 out of 50 cases (38 %). A statistically significant result was obtained (P = < 0.0001 and 0.017) for both PTEN and p16 genes. PTEN and p16 promoter methylation may be the main mechanism leading to the low expression of PTEN and p16 genes indicating the progress of tumor development. Our data suggest that a low PTEN and p16 expression due to methylation may contribute to the cancer progression and could be useful for prognosis of OSCC. Therefore, analysis of promoter methylation in such genes may provide a biomarker valuable for early detection of oral cancer.
引用
收藏
页码:7625 / 7632
页数:8
相关论文
共 50 条
  • [1] PTEN gene polymorphisms and susceptibility to oral squamous cell carcinoma in a Chinese Han population
    Yang, Xu-Dong
    Zhao, Su-Feng
    Zhang, Qian
    Li, Wei
    Wang, Yu-Xin
    Hong, Xiao-Wei
    Hu, Qin-Gang
    TUMOR BIOLOGY, 2016, 37 (01) : 577 - 582
  • [2] Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma
    Ohta, Shinsuke
    Uemura, Hiroji
    Matsui, Yoshiro
    Ishiguro, Hitoshi
    Fujinami, Kiyoshi
    Kondo, Keiichi
    Miyamoto, Hiroshi
    Yazawa, Takuya
    Danenberg, Kathleen
    Danenberg, Peter V.
    Tohnai, Iwai
    Kubota, Yoshinobu
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2009, 107 (01): : 81 - 91
  • [3] Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC)
    Kim, Soo Yeon
    Han, Yu Kyeong
    Song, Jae Min
    Lee, Chang Hun
    Kang, Keunsoo
    Yi, Joo Mi
    Park, Hae Ryoun
    CLINICAL EPIGENETICS, 2019, 11 (01)
  • [4] Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma
    Groebe, Alexander
    Hanken, Henning
    Kluwe, Lan
    Schoellchen, Maximilian
    Tribius, Silke
    Pohlenz, Philipp
    Clauditz, Till
    Grob, Tobias
    Simon, Ronald
    Sauter, Guido
    Heiland, Max
    Blessmann, Marco
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2013, 42 (09) : 676 - 681
  • [5] Role of CDKN2A/p16 expression in the prognostication of oral squamous cell carcinoma
    Padhi, Swati Shree
    Roy, Souvick
    Kar, Madhabananda
    Saha, Arka
    Roy, Shomereeta
    Adhya, Amit
    Baisakh, Manas
    Banerjee, Birendranath
    ORAL ONCOLOGY, 2017, 73 : 27 - 35
  • [6] HPV, protein p16 and squamous cell carcinoma of the oral cavity
    Blahak, Jiri
    Zelinka, Jiri
    Gumulec, Jaromir
    Machacek, Ctirad
    Danek, Zdenek
    Bulik, Oliver
    BIOMEDICAL PAPERS-OLOMOUC, 2020, 164 (03): : 292 - 299
  • [7] The significance of p16 protein expression in oral squamous cell carcinoma
    Malerova, S.
    Kalfert, D.
    Grega, M.
    Tachezy, R.
    Klozar, J.
    EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE, 2020, 69 (02): : 64 - 72
  • [8] P16 and human papillomavirus in sinonasal squamous cell carcinoma
    Cohen, Erin
    Coviello, Caitlin
    Menaker, Simon
    Martinez-Duarte, Ernesto
    Gomez, Carmen
    Lo, Kaming
    Kerr, Darcy
    Franzmann, Elizabeth
    Leibowitz, Jason
    Sargi, Zoukaa
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (08): : 2021 - 2029
  • [9] The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma
    Alexandre A. B. A. da Costa
    Felipe D’Almeida Costa
    Daniel Vilarim Araújo
    Marcos Pedro Guedes Camandaroba
    Victor Hugo Fonseca de Jesus
    Audrey Oliveira
    Ana Caroline Fonseca Alves
    Carlos Stecca
    Larissa Machado
    Andrea Cruz Feraz de Oliveira
    Thiago Bueno de Oliveira
    Ulisses Ribaldo Nicolau
    Vladmir Cláudio Cordeiro de Lima
    Medical Oncology, 2019, 36
  • [10] The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma
    da Costa, Alexandre A. B. A.
    Costa, Felipe D'Almeida
    Araujo, Daniel Vilarim
    Guedes Camandaroba, Marcos Pedro
    Fonseca de Jesus, Victor Hugo
    Oliveira, Audrey
    Fonseca Alves, Ana Caroline
    Stecca, Carlos
    Machado, Larissa
    Feraz de Oliveira, Andrea Cruz
    de Oliveira, Thiago Bueno
    Nicolau, Ulisses Ribaldo
    Cordeiro de Lima, Vladmir Claudio
    MEDICAL ONCOLOGY, 2019, 36 (01)